Request Deal Involvement

Valeant Pharmaceuticals and Pershing Square failed to acquire Allergan for $52bn.

Identify your role

Select the side you represented in this transaction, and provide your current job title.

Service Providers

Latham & Watkins

legal advisors

Latham & Watkins

Richards Layton and Finger

legal advisors

Richards Layton and Finger

Bank of America

financial advisors

Bank of America

Goldman Sachs

financial advisors

Goldman Sachs

Joele Frank

pr advisors

Joele Frank

Barclays

debt providers

Barclays

RBC Capital Markets

debt providers

RBC Capital Markets

Sard Verbinnen & Co

pr advisors

Sard Verbinnen & Co

Osler Hoskin & Harcourt

legal advisors

Osler Hoskin & Harcourt

RBC Capital Markets

financial advisors

RBC Capital Markets

Davies Ward Phillips & Vineberg

legal advisors

Davies Ward Phillips & Vineberg

Kirkland & Ellis

legal advisors

Kirkland & Ellis

Skadden Arps Slate Meagher & Flom

legal advisors

Skadden Arps Slate Meagher & Flom

Sullivan & Cromwell

legal advisors

Sullivan & Cromwell

Barclays

financial advisors

Barclays

Credit Suisse

financial advisors

Credit Suisse

or

Principals

ALLERGAN PLC

target

ALLERGAN PLC

VALEANT PHARMACEUTICALS

bidder

VALEANT PHARMACEUTICALS

PERSHING SQUARE CAPITAL MANAGEMENT LP

bidder

PERSHING SQUARE CAPITAL MANAGEMENT LP

Principals or Service Provider not listed?Add missing Service Provider or Principal

Enter your Job Title on this deal

This title will appear on your profile next to this deal involvement.


To help us verify your involvement, please include links to any relevant publications that mention you or your company's role in this deal:

All rights reserved. Copyright © 2025 Datasite

MergerLinks - Request Credit - Valeant Pharmaceuticals and Pershing Square failed to acquire Allergan for $52bn.